Current position

Cathie Wood’s Teva Pharmaceutical Industries (TEVA) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

ARK Investment ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ4 2017Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares512.44KHighest verified quarter-end share count
Quarters reported34Verified quarters with shares above zero
What happened?

ARK Investment Management first reported Teva Pharmaceutical Industries in Q4 2017. The reported position was increased and reduced across later filings. ARK Investment Management currently reports 68.65K shares. The latest verified filing showed: Bought 0.5% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 0.5% more+374 shares · 68.65K shares reported after the change
Filing context

Quarter-end price $33.88 · Estimated holding basis $11.76

Q1 2026
Sold 35.1% of the position−36.85K shares · 68.28K shares remained
Filing context

Quarter-end price $30.12 · Estimated holding basis $11.64

Q4 2025
Sold 11.4% of the position−13.59K shares · 105.13K shares remained
Filing context

Quarter-end price $31.21 · Estimated holding basis $11.64

Q3 2025
Sold 1.8% of the position−2.15K shares · 118.72K shares remained
Filing context

Quarter-end price $20.20 · Estimated holding basis $11.64

Q2 2025
Bought 33.9% more+30.62K shares · 120.87K shares reported after the change
Filing context

Quarter-end price $16.76 · Estimated holding basis $11.64

Q1 2025
Sold 10.1% of the position−10.19K shares · 90.25K shares remained
Filing context

Quarter-end price $15.37 · Estimated holding basis $9.90

Portfolio importance

How important is Teva Pharmaceutical Industries in ARK Investment Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q2 2026
Current rank#142of 190 reported positions
Peak portfolio weight0.0%Q2 2018
Best historical rank#105Q2 2018
At peak importanceQ2 2018
TEVA
0.0%
Largest holding
5.6%
Cross-investor discovery

Who else owns Teva Pharmaceutical Industries?

Also reported by 3 other tracked investors in their latest verified filings.

David EinhornDME Capital Management
TEVA2.5% of reported portfolio
Stanley DruckenmillerDuquesne Family Office
TEVA0.5% of reported portfolio
Ray DalioBridgewater Associates, LP
TEVA0.2% of reported portfolio
Explore Teva Pharmaceutical Industries across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$39.252026-09-15

Market context only; not an investor transaction price.

Latest filing quarter-end price$33.88Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$11.76Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows ARK Investment Management’s aggregated Form 13F disclosures. It is not Cathie Wood’s personal brokerage account, and 13F filings do not reveal exact trade dates or execution prices.